Search filters

Filters
Clear All

Phase

  • 1
  • 6
  • 7
  • 6
  • 7

Found 7 Lymphoproliferative disorders trials

A listing of Lymphoproliferative disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:
99 years or below
All genders
Please refer to Section 6 of the full protocol (Study Objectives). Please refer to Section 12 of the full protocol (Statistical Analysis). Please refer to Section 12 of the full protocol (Statistical Analysis).
99 years or below
All genders
To identify novel gene and protein targets in biospecimens of patients with EBV-associated lymphoproliferative disorders who are enrolled to L-RAD (IRB #832203).
99 years or below
All genders
Please refer to Section 6 of the full protocol (Study Objectives). Please refer to Section 13 of the full protocol (Statistical Analysis). Please refer to Section 13 of the full protocol (Statistical Analysis).
99 years or below
All genders
To support the research of lymphoproliferative disorders (LPDs) by supplementing the main repository (IRB #832203) with biospecimens (i.e., tissue and fluid) obtained solely for the purpose of research. These materials will be used for future, unspecified research.
99 years or below
All genders
To explore secondary malignancies in subjects enrolled to the L-RAD study (IRB #832203, Lymphoproliferative Disorders: Biological Specimen Repository and Clinical Database) who received CAR T-cells or other T-cell directed therapies for lymphoproliferative disorders and to investigate potential relationships between prior T-cell directed therapy for lymphoma and subsequent malignancies.
99 years or below
All genders
To develop PDX models or tumor cell lines of tumors from subjects with lymphoproliferative disorders enrolled to L-RAD (IRB #832203).
18 years or above
All genders
Phase 1/2
Interventional
This study investigates the safety and tolerability of an investigational medication in patients with advanced solid tumors and lymphomas. The study is divided into two phases: Phase 1 focuses on finding the maximum tolerated dose of the investigational medication, while Phase 2 evaluates its antitumor activity across different types of …